1. |
何林燁, 王藝超, 李志輝. 2022年中國甲狀腺癌流行情況分析: 基于《中國腫瘤登記年報》2005–2018年數據. 中國普外基礎與臨床雜志, 2024, 31(7): 790-795.
|
2. |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024, 4(1): 47-53.
|
3. |
Malaguarnera R, Vella V, Pellegriti G, et al. Editorial: Clinical and molecular epidemiology of thyroid cancer of follicular origin. Front Endocrinol (Lausanne), 2018, 9: 67. doi: 10.3389/fendo.2018.00067.
|
4. |
呂恬, 王佳峰, 徐加杰, 等. 《中國腫瘤整合診治指南—CACA甲狀腺癌診治指南》外科部分解讀. 中國普外基礎與臨床雜志, 2023, 30(2): 154-159.
|
5. |
Sui C, Liang N, Du R, et al. Time trend analysis of thyroid cancer surgery in China: single institutional database analysis of 15 000 patients. Endocrine, 2020, 68(3): 617-628.
|
6. |
Boucai L, Zafereo M, Cabanillas M E. Thyroid cancer: A review. JAMA, 2024, 331(5): 425-435.
|
7. |
凡中霞, 王永波. 甲狀腺癌患者術后特異性生活質量的現狀及其影響因素分析. 中國普外基礎與臨床雜志, 2024, 31(7): 840-847.
|
8. |
田文, 劉軍言. 中國甲狀腺外科近十年成就. 西安交通大學學報(醫學版), 2024, 45(1): 1-8.
|
9. |
中華醫學會內分泌學分會, 中華醫學會外科學分會甲狀腺及代謝外科學組, 中國抗癌協會頭頸腫瘤專業委員會, 等. 甲狀腺結節和分化型甲狀腺癌診治指南(第二版). 中華內分泌代謝雜志, 2023, 39(3): 181-226.
|
10. |
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016, 26(1): 1-133.
|
11. |
鄭傳銘, 徐加杰, 蔣烈浩, 等. 無充氣腋窩入路完全腔鏡下甲狀腺葉切除的方法—葛-鄭氏七步法. 中國普通外科雜志, 2019, 28(11): 1336-1341.
|
12. |
Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization classification of thyroid tumors: A standardized diagnostic approach. Endocrinol Metab (Seoul), 2022, 37(5): 703-718.
|
13. |
Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (Eighth Edition): What changed and why?. Thyroid, 2017, 27(6): 751-756.
|
14. |
萬麗, 趙晴, 陳軍, 等. 疼痛評估量表應用的中國專家共識(2020版). 中華疼痛學雜志, 2020, 16(3): 177-187.
|
15. |
Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab, 2007, 92(9): 3590-3594.
|
16. |
Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab, 2007, 92(7): 2487-2495.
|
17. |
Frasoldati A, Pesenti M, Gallo M, et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer, 2003, 97(1): 90-96.
|
18. |
Brown BC, McKenna SP, Siddhi K, et al. The hidden cost of skin scars: quality of life after skin scarring. J Plast Reconstr Aesthet Surg, 2008, 61(9): 1049-1058.
|
19. |
徐加杰, 張李卓, 張啟弘, 等. 無充氣經腋窩腔鏡甲狀腺手術的臨床應用. 中華耳鼻咽喉頭頸外科雜志, 2020, 55(10): 913-920.
|
20. |
陳孝磊, 李超, 周雨秋, 等. 經腋無充氣腔鏡與傳統頸部開放手術治療PTC的療效分析. 中華耳鼻咽喉頭頸外科雜志, 2023, 58(4): 351-357.
|
21. |
Qu Y, Han Y, Wang W, et al. Clinical analysis of total endoscopic thyroidectomy via breast areola approach in early differentiated thyroid cancer. J BUON, 2021, 26(3): 1022-1027.
|
22. |
來益, 沈宇玲, 王家東. 不同入路腔鏡甲狀腺手術和傳統開放甲狀腺手術療效分析. 中國眼耳鼻喉科雜志, 2023, 23(1): 34-38.
|
23. |
郭湃, 張浩, 張云生, 等. 腋窩入路無充氣腔鏡手術與開放性甲狀腺癌根治術對甲狀腺癌患者頸部功能的影響分析. 中國實用醫藥, 2024, 19(4): 53-56.
|
24. |
孫思雨, 張晨嵩, 謝波, 等. 經腋窩入路免充氣全腔鏡甲狀腺癌根治術和開放甲狀腺癌根治術療效對比. 蚌埠醫學院學報, 2021, 46(2): 173-175, 178.
|
25. |
Jeong JJ, Kang SW, Yun JS, et al. Comparative study of endoscopic thyroidectomy versus conventional open thyroidectomy in papillary thyroid microcarcinoma (PTMC) patients. J Surg Oncol, 2009, 100(6): 477-480.
|
26. |
Kang SW, Jeong JJ, Yun JS, et al. Gasless endoscopic thyroidectomy using trans-axillary approach; surgical outcome of 581 patients. Endocr J, 2009, 56(3): 361-369.
|
27. |
渠寧, 王鈺婷, 馬奔, 等. 2022年度甲狀腺癌研究及診療新進展. 中國癌癥雜志, 2023, 33(5): 423-430.
|
28. |
周余, 程若川, 李想. 合并橋本氏甲狀腺炎對甲狀腺乳頭狀癌臨床侵襲性影響的回顧性分析. 中華內分泌外科雜志, 2022, 16(1): 41-44.
|
29. |
丁科, 黃江生, 汪明明, 等. 腔鏡與開放手術治療低危型甲狀腺乳頭狀癌的療效比較: 附538例報告. 中國普通外科雜志, 2019, 28(5): 524-531.
|
30. |
Jiang WJ, Yan PJ, Zhao CL, et al. Comparison of total endoscopic thyroidectomy with conventional open thyroidectomy for treatment of papillary thyroid cancer: a systematic review and meta-analysis. Surg Endosc, 2020, 34(5): 1891-1903.
|
31. |
Zhang X, Li JG, Zhang SZ, et al. Comparison of indocyanine green and carbon nanoparticles in endoscopic techniques for central lymph nodes dissection in patients with papillary thyroid cancer. Surg Endosc, 2020, 34(12): 5354-5359.
|
32. |
Chen S, Hou X, Hua S, et al. Mitoxantrone hydrochloride injection for tracing helps to decrease parathyroid gland resection and increase lymph node yield in thyroid cancer surgery: a randomized clinical trial. Am J Cancer Res, 2022, 12(9): 4439-4447.
|
33. |
鄭傳銘, 徐加杰, 王佳峰, 等. 無充氣腋窩入路腔鏡甲狀腺手術的進展與展望. 中國普外基礎與臨床雜志, 2021, 28(10): 1266-1269.
|
34. |
Ding Y, Qiu C, Zhu C, et al. Comparison of gasless transaxillary endoscopic thyroidectomy, endoscopic thyroidectomy via areola approach and conventional open thyroidectomy in patients with unilateral papillary thyroid carcinoma. World J Surg Oncol, 2024, 22(1): 148. doi: 10.1186/s12957-024-03433-2.
|
35. |
Zou M, Baitei EY, Al-Rijjal RA, et al. TSH overcomes BrafV600E-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. Oncogene, 2016, 35(15): 1909-1918.
|
36. |
Van Uytfanghe K, Ehrenkranz J, Halsall D, et al. Thyroid stimulating hormone and thyroid hormones (Triiodothyronine and Thyroxine): An American Thyroid Association—Commissioned review of current clinical and laboratory status. Thyroid, 2023, 33(9): 1013-1028.
|
37. |
Haymart MR, Glinberg SL, Liu J, et al. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf), 2009, 71(3): 434-439.
|
38. |
Giovanella L, Ceriani L, Suriano S, et al. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxf), 2008, 69(4): 659-663.
|
39. |
Hsieh CJ, Wang PW. Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma. Thyroid, 2014, 24(3): 488-493.
|